WGS stock icon

GeneDx Holdings

75.43 USD
+3.66
5.10%
At close Dec 13, 4:00 PM EST
After hours
75.43
+0.00
0.00%
1 day
5.10%
5 days
-1.23%
1 month
-3.89%
3 months
99.18%
6 months
162.18%
Year to date
2,757.20%
1 year
3,912.23%
5 years
-80.73%
10 years
-80.73%
 

About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Employees: 1,000

0
Funds holding %
of 6,805 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

714% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 7

85% more capital invested

Capital invested by funds: $432M [Q2] → $799M (+$368M) [Q3]

83% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 23

58% more funds holding

Funds holding: 86 [Q2] → 136 (+50) [Q3]

6.73% more ownership

Funds ownership: 63.18% [Q2] → 69.91% (+6.73%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]

38% less call options, than puts

Call options by funds: $4.15M | Put options by funds: $6.74M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$54
28%
downside
Avg. target
$73
3%
downside
High target
$95
26%
upside

5 analyst ratings

positive
40%
neutral
60%
negative
0%
Goldman Sachs
Matthew Sykes
62% 1-year accuracy
28 / 45 met price target
7%downside
$70
Neutral
Maintained
30 Oct 2024
Wells Fargo
Brandon Couillard
50% 1-year accuracy
9 / 18 met price target
1%downside
$75
Equal-Weight
Maintained
30 Oct 2024
Craig-Hallum
Bill Bonello
67% 1-year accuracy
4 / 6 met price target
26%upside
$95
Buy
Maintained
30 Oct 2024
Craig-Hallum
Bill Bonello
67% 1-year accuracy
4 / 6 met price target
7%downside
$70
Buy
Maintained
24 Oct 2024
Goldman Sachs
Matthew Sykes
62% 1-year accuracy
28 / 45 met price target
28%downside
$54
Neutral
Maintained
16 Oct 2024

Financial journalist opinion

Based on 6 articles about WGS published over the past 30 days

Neutral
Business Wire
1 week ago
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
Positive
Investors Business Daily
2 weeks ago
This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win
Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.
This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win
Neutral
Business Wire
3 weeks ago
GeneDx to Participate in Upcoming Investor Conference
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.
GeneDx to Participate in Upcoming Investor Conference
Neutral
Business Wire
3 weeks ago
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx's robust database - to improve all stages of drug development. The new offering is part of GeneDx's ongoing investment to deliver personalized and actionable health insights to.
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
Neutral
Business Wire
3 weeks ago
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corpor.
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
Positive
The Motley Fool
4 weeks ago
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Neutral
Business Wire
1 month ago
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children's Hospital, was conducted on nearly 187,000 samples performed and a.
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
Neutral
Business Wire
1 month ago
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be presented across six platform presentations and five posters and will unveil findings from key research initiatives constructed on the backbones of its industry leading diverse dataset of more than 700,000 clinical exome and genomes.
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
Positive
Zacks Investment Research
1 month ago
3 Stocks to Buy for Stellar Earnings Acceleration in November
Stocks like Snap, GeneDx Holdings and Leonardo DRS exhibit solid earnings acceleration.
3 Stocks to Buy for Stellar Earnings Acceleration in November
Positive
Zacks Investment Research
1 month ago
Best Momentum Stocks to Buy for November 4th
WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024.
Best Momentum Stocks to Buy for November 4th
Charts implemented using Lightweight Charts™